DEFENCE THERAPEUTICS SUCCESS IN
TESTING IT'S COVID-19 ACCUVAC-PT001 VACCINE IN A NON-RODENT
MODEL
Vancouver, BC,
Canada, September 14th,
2021 -- InvestorsHub
NewsWire -- Defence Therapeutics Inc.
(CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"
or the "Company"),
a biotechnology company working on cancer therapeutics and
infectious disease vaccines, is pleased to announce the completion
of a non-GLP study on rabbits demonstrating a potent humoral
response with titer reaching 1:43 000 000 per average without any
signs of toxicity.
Defence
has previously developed and tested its AccuVAC-PT001
vaccine
in mice. This vaccine is highly immunogenic, and the generated
antibodies cross-reacted with all tested variants including the
Delta strain. In addition to the mechanistic and neutralization
studies, Defence re-tested its vaccine in rabbits with a Contract
Research Organization (CRO), as a second non-rodent animal model.
The rabbits vaccinated with our AccuVAC-PT001 developed a very
strong humoral response, and physical inspection conducted over a
42-day period presented no change in body weight, behaviour,
activity or appearance of any rashes at injection
sites.
"Defence's
next step is a GLP study that will enable us to present our
product, AccuVAC-PT001, to Health Canada and the FDA. Once cleared,
Defence can initiate a Phase I/IIa on its COVID vaccine in healthy
individuals". says Mr. Plouffe, the CEO of Defence
Therapeutics.
"Defence's Accum
technology is highly versatile and can be applied to any protein.
Results have demonstrated from past and current vaccine studies
that the AccuVAC-PT001 platform enables the design of novel
protein-based vaccines, that will amplify the immune response that
can be generated by current vaccines," Mr Plouffe
stated.
This virus is evolving
very rapidly to escape the vaccine-induced immunity. The data
obtained with AccuVAC-PT001 not only provides evidence that the
vaccine is efficient against a wide range of currently circulating
variants, but it also highlights the importance of continuing
research and development to effectively neutralize new variants and
future mutations.
Additional
Information:
The Company makes no
express or implied claims that it has developed a vaccine to treat
COVID-19 (or SARS-2 Coronavirus) at this time.
Dr. Moutih Rafei,
Defence's VP Research and Development, has reviewed and approved
the scientific disclosure contained in this press
release.
Dr. Rafei has a PhD in
Experimental Medicine from McGill University and received his
post-doctoral training at Université de Montréal. He is an
immuno-oncologist who specializes in the fields of T-cell
development, stem cell biology, cancer immunotherapy and autoimmune
diseases.
About
Defence:
Defence
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
technology,
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells. As a result, increased efficacy
and potency can be reached against catastrophic illness such as
cancer and infectious diseases.
For further
information:
Sebastien Plouffe,
President, CEO and Director
P: (514)
947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
change.
Neither the
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.
Defence Therapeutics (QB) (USOTC:DTCFF)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Defence Therapeutics (QB) (USOTC:DTCFF)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
